Factors affecting surgical management following neoadjuvant therapy in patients with primary her2-positive breast cancer: Results from the neoaltto phase iii trial

Annals of Oncology

Volumn 25, Issue 4, 2014, Pages 910-911

  Criscitiello, C ^a   Azim, H A ^b   de Azambuja, E ^b   Rubio, I T ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b BrEAST Data Centre   (Belgium)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; DECISION MAKING; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; LETTER; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE; ADJUVANT THERAPY; BREAST NEOPLASMS; FEMALE; METABOLISM; SEGMENTAL MASTECTOMY;

BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2;

EID: 84897059158     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu034     Document Type: Letter

References (8)

1. Barry P, Schiavon G, MacNeill F. Letter to the editor on 'Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2- positive breast cancer: results from the NeoALTTO phase III trial'. Ann Oncol 2014; 25: 909-910.
2. Criscitiello C, Azim HA, Jr, Agbor-Tarh D et al. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol 2013; 24(8): 1980-1985.
3. Baselga J, Bradbury I, Eidtmann H et al. NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
4. Katipamula R, Degnim AC, Hoskin T et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 2009;27(25):4082-4088.
5. Pengel KE, Loo CE, Teertstra HJ et al. The impact of preoperative MRI on breastconserving surgery of invasive cancer: a comparative cohort study. Breast Cancer Res Treat 2009;116:161-169.
6. Bleicher RJ, Ciocca RM, Egleston BL et al. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 2009;209:180-187.
7. Turnbull L, Brown S, Harvey I et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet 2010;375(9714):563-571.
8. Cebrecos I, Cordoba O, Deu J et al. Can we predict local recurrence in breast conserving surgery neoadjuvant chemotherapy? Eur J Surg Oncol 2010;36 (6):528-534.